115 related articles for article (PubMed ID: 28903907)
1. Research progress on genetic heterogeneity between primary and paired metastatic colorectal cancer.
Lu YW; Wang KH
Yi Chuan; 2017 Jun; 39(6):482-490. PubMed ID: 28903907
[TBL] [Abstract][Full Text] [Related]
2. Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis.
Wei Q; Ye Z; Zhong X; Li L; Wang C; Myers RE; Palazzo JP; Fortuna D; Yan A; Waldman SA; Chen X; Posey JA; Basu-Mallick A; Jiang BH; Hou L; Shu J; Sun Y; Xing J; Li B; Yang H
Ann Oncol; 2017 Sep; 28(9):2135-2141. PubMed ID: 28911083
[TBL] [Abstract][Full Text] [Related]
3. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
4. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
[TBL] [Abstract][Full Text] [Related]
5. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.
Kim TM; Jung SH; An CH; Lee SH; Baek IP; Kim MS; Park SW; Rhee JK; Lee SH; Chung YJ
Clin Cancer Res; 2015 Oct; 21(19):4461-72. PubMed ID: 25979483
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP
Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
8. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.
Jeantet M; Tougeron D; Tachon G; Cortes U; Archambaut C; Fromont G; Karayan-Tapon L
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916952
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure?
Li Z; Jin K; Lan H; Teng L
Hepatogastroenterology; 2011; 58(106):411-6. PubMed ID: 21661405
[TBL] [Abstract][Full Text] [Related]
10. Proteome Heterogeneity in Colorectal Cancer.
Lim LC; Lim YM
Proteomics; 2018 Feb; 18(3-4):. PubMed ID: 29316255
[TBL] [Abstract][Full Text] [Related]
11. Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer.
Jesinghaus M; Wolf T; Pfarr N; Muckenhuber A; Ahadova A; Warth A; Goeppert B; Sers C; Kloor M; Endris V; Stenzinger A; Weichert W
Am J Surg Pathol; 2015 Aug; 39(8):1140-7. PubMed ID: 25786087
[TBL] [Abstract][Full Text] [Related]
12. Colorectal Cancer Genetic Heterogeneity Delineated by Multi-Region Sequencing.
Lu YW; Zhang HF; Liang R; Xie ZR; Luo HY; Zeng YJ; Xu Y; Wang LM; Kong XY; Wang KH
PLoS One; 2016; 11(3):e0152673. PubMed ID: 27023146
[TBL] [Abstract][Full Text] [Related]
13. The path to metastatic mouse models of colorectal cancer.
Romano G; Chagani S; Kwong LN
Oncogene; 2018 May; 37(19):2481-2489. PubMed ID: 29463860
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Shibuya H; Eshima K
Dis Colon Rectum; 2011 Sep; 54(9):1170-8. PubMed ID: 21825899
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
16. FOXC2 promotes colorectal cancer metastasis by directly targeting MET.
Cui YM; Jiao HL; Ye YP; Chen CM; Wang JX; Tang N; Li TT; Lin J; Qi L; Wu P; Wang SY; He MR; Liang L; Bian XW; Liao WT; Ding YQ
Oncogene; 2015 Aug; 34(33):4379-90. PubMed ID: 25381815
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
18. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.
Chen J; Ye Y; Sun H; Shi G
Cancer Chemother Pharmacol; 2013 Jan; 71(1):265-72. PubMed ID: 23090619
[TBL] [Abstract][Full Text] [Related]
19. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.
Sartore-Bianchi A; Bencardino K; Cassingena A; Venturini F; Funaioli C; Cipani T; Amatu A; Pietrogiovanna L; Schiavo R; Di Nicolantonio F; Artale S; Bardelli A; Siena S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S1-5. PubMed ID: 21129603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
